2007
DOI: 10.1200/jco.2007.13.6879
|View full text |Cite
|
Sign up to set email alerts
|

Questions About Gemcitabine Dose Rate: Answered or Unanswered?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
14
0

Year Published

2008
2008
2011
2011

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(14 citation statements)
references
References 24 publications
0
14
0
Order By: Relevance
“…Given the schedule-dependent activity of dFdC, alternative dosing schedules may yield better responses. The more prolonged exposure of an oral dose also mimics more closely the exposure to dFdC after a fixed dose rate schedule, which is receiving more interest of late (40,41). Lastly, THU could sensitize tumors and organ environments to dFdC by blocking highly expressed CD.…”
Section: Discussionmentioning
confidence: 99%
“…Given the schedule-dependent activity of dFdC, alternative dosing schedules may yield better responses. The more prolonged exposure of an oral dose also mimics more closely the exposure to dFdC after a fixed dose rate schedule, which is receiving more interest of late (40,41). Lastly, THU could sensitize tumors and organ environments to dFdC by blocking highly expressed CD.…”
Section: Discussionmentioning
confidence: 99%
“…However, laboratory data from our institution identified a maximal synergistic effect for the combination when cyclophosphamide is given 4 h after initiation of the gemcitabine infusion [[1,13,14,15,16,17]; Plunkett, pers. commun.…”
Section: Discussionmentioning
confidence: 99%
“…Despite these initial promising results, other studies with gemcitabine alone or in combination with other drugs (cisplatin, carboplatin, paclitaxel) failed to show any clinical benefit in favor of FDR infusion [9] . Our Institution in collaboration with other Italian Centers [17] reported a similar survival for patients with NSCLC (non-small cell lung cancer) treated with gemcitabine 1000 mg/m 2 in 30 minutes standard infusion or 100 minutes.…”
Section: Introductionmentioning
confidence: 99%
“…Commonly, doses of gemcitabine ranging between 800 and 2800 mg/m 2 are generally administered by intravenous infusion over 30 minutes [8,9] , there is evidence that this generates plasma gemcitabine concentrations that greatly exceed ( 60µmol/L) the levels that saturate the rate of triphoshate accumulation (10 to 20 µmol/L) [6,10] .…”
Section: Introductionmentioning
confidence: 99%